Kidney transplantation from HCV-positive donors

Kidney transplantation from HCV-positive donors is a contested but potentially valuable response to the persistent shortage of transplantable kidneys. Its central logic is a calculated exchange: an HCV-positive recipient may accept a kidney carrying a transmission risk in order to leave dialysis sooner, while the transplant system avoids discarding organs that could provide useful graft function. The strategy is not equivalent to treating donor seropositivity as harmless. Early Spanish experience showed that transplantation could be short-term safe in selected HCV-positive recipients, yet retrospective RNA testing also documented transmission and chronic liver disease, leading to a more restrictive policy centered on recipients with active viremia.

Definition and Clinical Setting

Kidney transplantation from HCV-positive donors concerns the use of kidneys from donors with positive hepatitis C serology, generally described as HCVD+, for recipients already infected with HCV. It emerged within a widening gap between the supply of organs and the number of people waiting for them. At the end of 2009, approximately 63,000 patients were on an organ waiting list in the European Union while about 28,000 transplant procedures were performed during the year; in the United States, almost 111,000 people were registered in May 2011, with roughly 28,000 transplant procedures performed annually. Many candidates consequently deteriorate or die before transplantation. The shortage has encouraged the use of expanded-criteria and non-standard-risk donors, but the two categories carry different hazards: expanded-criteria organs may have reduced graft survival, whereas non-standard-risk organs may transmit disease. Because HCV can be transmitted through organ transplantation, kidneys from HCV-positive donors remain controversial. Some centers never accept them, and some countries have technical or legal provisions prohibiting their use. The question is therefore not simply whether such kidneys are safe, but whether potentially usable organs should be discarded when a recipient may reasonably accept the risk.

Early Experience and Transmission Risk

In March 1990, two Spanish kidney transplant units began a pilot program using kidneys from HCV-positive donors for HCV-positive recipients. The initial short-term results were reassuring: graft and patient survival among HCV-positive recipients was similar whether the donor was HCV-positive or HCV-negative, and comparable proportions developed biochemical evidence of chronic liver disease, defined as alanine aminotransferase levels exceeding 2.5 times the upper limit of normal for more than six consecutive months. The apparent safety of the policy did not mean that transmission had been eliminated. When donor and recipient HCV RNA were later assessed by polymerase chain reaction, five recipients who had been RNA-negative before transplantation were found to have received kidneys from donors with positive HCV RNA. Four became RNA-positive after transplantation, and two developed chronic liver disease according to the study definition. In March 1993, the Spanish groups therefore changed their policy: kidneys from HCV-positive donors were limited to candidates who already had positive HCV RNA before transplantation. This distinction between serology and active viremia is decisive. HCV antibody indicates exposure, whereas detectable HCV RNA identifies active infection relevant to transmission risk and recipient selection. The Spanish experience showed that pre-existing HCV positivity alone was not sufficient protection against acquiring a new infection from the graft. The recommended approach consequently became narrower: an HCV-positive donor kidney should be offered only to a waiting-list candidate with detectable HCV RNA who has consented in advance to receive such an organ.

Benefits, Comparisons, and Uncertainty

Later single-center experiences using the same basic approach reported similar short-term outcomes when HCV-positive recipients received kidneys from HCV-positive rather than HCV-negative donors. Several series identified a practical advantage that could matter as much as a laboratory endpoint: recipients of HCV-positive kidneys spent significantly less time on the waiting list. For patients unlikely to achieve sustained virologic response, unable or unwilling to undergo interferon-based treatment, or unable to remain safely on dialysis, earlier transplantation could offer a more favorable course than continued dialysis. The evidence is not uniformly reassuring. Registry analyses using the United States Renal Data System described lower patient survival after transplantation from HCV-positive rather than HCV-negative donors, regardless of the recipient's HCV serology; the difference became apparent approximately two years after transplantation. A higher incidence of post-transplant diabetes mellitus among recipients of HCV-positive kidneys was proposed as an intermediate complication that might help explain the later excess mortality. These findings led investigators to urge caution and complete information for potential recipients, rather than treating the favorable short-term center-based results as conclusive proof of long-term equivalence. The tension is intensified by the clinical burden of active HCV in end-stage renal disease. HCV-related liver disease is often asymptomatic in patients on long-term dialysis, even though biochemical abnormalities may be present. HCV infection has also been associated with impaired mental quality of life in dialysis patients, and HCV viremia has been linked in one prospective study to aortic stiffness and poorer cardiovascular event-free survival. At the same time, antiviral treatment can produce flu-like symptoms, anemia, neutropenia, depression, and anxiety; toxicity leads to dose reduction in roughly 35–42% of patients and treatment discontinuation in about 30%. The decision to accept an HCV-positive kidney therefore weighs transmission and possible later complications against the medical, psychological, and temporal costs of remaining on dialysis.

Selection, Consent, and Management

The selection rule developed from the Spanish experience is explicit: HCV-positive kidneys should be restricted to HCV RNA-positive recipients on the waiting list. Candidates should agree beforehand to receive an organ from an HCV-positive donor, because the intervention knowingly accepts a disease-related hazard rather than discovering it only after transplantation. This requirement makes consent part of the allocation strategy, not a procedural detail added after the organ has been offered. The broader transplant evaluation must establish the recipient's virologic and hepatic status. HCV-positive kidney transplant candidates should be screened with antibody testing and, where appropriate, nucleic acid testing; active infection requires assessment of liver injury. Among candidates with active HCV, liver biopsy remained the gold standard in the evidence reviewed, and the KDIGO Workgroup recommended percutaneous biopsy during evaluation because available noninvasive tests did not provide equivalent accuracy. Ten to twenty-five percent of pre-kidney transplant candidates had advanced liver injury, including stage 3 or 4 disease, when biopsied. Established or decompensated cirrhosis should prompt referral to a liver transplant team for consideration of simultaneous liver-kidney transplantation rather than proceeding automatically with kidney-only transplantation. Patients on the kidney waiting list require continuing surveillance because waiting times in some United States regions approached five to seven years. Candidates not previously tested should undergo anti-HCV antibody screening with confirmation by nucleic acid testing in low-prevalence regions, or direct nucleic acid testing in high-prevalence settings. A positive nucleic acid test should place the candidate on hold and trigger hepatology assessment and possible treatment. Patients who achieved sustained virologic response should have nucleic acid testing at least annually to confirm its durability; relapse should likewise lead to hold status and consideration of retreatment. Candidates who remain viremic should receive regular evaluation for progression of liver disease.

Antiviral Treatment and Organ Utilization

Pretransplant antiviral therapy can eliminate HCV before transplantation and may reduce the later risk of post-transplant diabetes or immune-complex glomerular disease in the allograft, although benefits for graft and patient survival had not been established. Interferon after transplantation is especially problematic because it is associated with an increased risk of renal allograft rejection. For that reason, efforts to eradicate HCV are preferably concentrated before transplantation. Yet pretransplant treatment is not universally feasible. Interferon-based therapy may be prolonged, expensive, poorly tolerated, and unsuccessful; patients may refuse it, withdraw from it, or fail to respond, and treatment may require exclusion from the waiting list. For this group of HCV RNA-positive candidates, transplantation with an HCV-positive kidney can remain a rational option because their expected course may be more favorable than continued dialysis and because the strategy may substantially reduce waiting time. The need for such a strategy may diminish as screening, preventive measures, and antiviral treatment reduce active HCV among patients with end-stage renal disease and on transplant waiting lists. Paradoxically, that success can make HCV-positive kidneys more likely to become surplus organs because fewer appropriate HCV RNA-positive recipients remain. Variation between transplant centers compounds the problem: HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys. Organizational systems that redirect these kidneys to suitable recipients, including preemptive transplantation for HCV-positive candidates who are not going to receive interferon therapy, were therefore proposed as a way to increase utilization without abandoning virologic safeguards.

Significance

Kidney transplantation from HCV-positive donors embodies the ethical and clinical pressure created by organ scarcity. It neither converts HCV into a negligible risk nor justifies unrestricted use of infected organs. Its defensible form is selective and transparent: identify active HCV in the recipient, stage liver disease, exclude candidates whose hepatic condition requires a liver-centered strategy, disclose the possibility of donor-derived infection and later complications, and obtain consent before transplantation. The concept also exposes how transplantation is governed by competing definitions of benefit. A kidney judged unsuitable in one center may be a valuable opportunity in another for a recipient facing years of dialysis, treatment toxicity, diminished quality of life, and progressive illness. The decisive comparison is therefore not HCV-positive versus HCV-negative in isolation, but a carefully monitored HCV-positive graft versus the concrete risks of waiting. Evidence of transmission, later survival differences, post-transplant diabetes, and shorter waiting time keeps that comparison unresolved, but it also explains why the policy persists as a restricted option rather than disappearing altogether.